6 To 7 Amino Acid Residues In Defined Sequence Patents (Class 530/329)
  • PEPTIDE DERIVATIVES AND USE THEREOF AS CARRIERS FOR MOLECULES IN THE FORM OF CONJUGATES
    Publication number: 20110230416
    Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise molecules of pharmaceutical or diagnostic interest, such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes, and notably to promote their transport across the blood-brain barrier (BBB).
    Type: Application
    Filed: October 20, 2009
    Publication date: September 22, 2011
    Applicants: Vect-Horus, Centre National De La Recherche Scientifique, Universite De La Mediterranee
    Inventors: Michel Khrestchatisky, Marion David, Yves Molion, Patrick Vlieghe
  • Contrast Agents For Detecting Protease Activity By Means Of Hyperpolarization And For Stratifying Patients
    Publication number: 20110229414
    Abstract: A contrast agent is disclosed for imaging methods. In at least one embodiment the contrast agent includes a construct including i) at least two copies of a substrate for at least one tumor-specific protease, and ii) at least one linker having at least one recognition site for at least one tumor-specific protease, wherein a hyperpolarization site is located at the N and/or C terminus of the substrate, and wherein the linker is configured such that the hydrophobic ends of the substrate interact and form a central core by means of noncovalent interactions with the lipophilic residues, and the contrast agent together with a parahydrogen metal template for use in an imaging method for diagnosing a tumor.
    Type: Application
    Filed: January 25, 2011
    Publication date: September 22, 2011
    Applicants: SIEMENS AKTIENGESELLSCHAFT, SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Christian Geppert, Arne Hengerer, Sven Meyburg, Sebastian Schmidt, Susanne Schmolke, Ralph Markus Wirtz
  • Compositions and methods for topical application and transdermal delivery of an oligopeptide
    Patent number: 8022179
    Abstract: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: September 20, 2011
    Assignee: Revance Therapeutics, Inc.
    Inventors: Michael D. Dake, Jacob M. Waugh
  • Method for preventing and treating Alzheimer's disease
    Patent number: 8022180
    Abstract: The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal A?42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal A?42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: September 20, 2011
    Assignee: Affiris Forschungs-und Entwicklungs GmbH
    Inventors: Frank Mattner, Walter Schmidt
  • Isolated antibodies against biologically active leptin-related peptides
    Patent number: 8022189
    Abstract: The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: September 20, 2011
    Assignee: Albany Medical College
    Inventors: Patricia Grasso, Daniel W. Lee, Matthew C. Leinung
  • CATIONIC CORE-SHELL PEPTIDE NONOPARTICLES
    Publication number: 20110223202
    Abstract: The invention discloses an amphiphilic antimicrobial substance comprising a hydrophobic portion coupled to a cationic oligopeptide portion. The cationic oligopeptide portion may comprise a protein transduction domain coupled to a cationic oligopeptide group.
    Type: Application
    Filed: December 18, 2008
    Publication date: September 15, 2011
    Inventors: Yi-Yan Yang, Lihong Liu
  • Immune-modulating peptide
    Patent number: 8017572
    Abstract: Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: September 13, 2011
    Assignee: Posco
    Inventors: Sung-Ho Ryu, Pann-Ghill Suh, Yoe-Sik Bae, Ji-Young Song
  • Anti-inflammatory compounds and uses thereof
    Patent number: 8017726
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: September 13, 2011
    Assignee: Yale University
    Inventors: Michael J. May, Sankar Ghosh
  • Nanographite structure/metal nanoparticle composite
    Patent number: 8017729
    Abstract: The present invention makes it possible to efficiently recognize carbon nanotubes, carbon nanohorns or modifiers thereof and to support functional compounds by fusing the ability of ferritin molecules capable of forming nanoparticles of inorganic metal atoms or inorganic metal compounds. In addition, because ferritin molecules are capable of forming two-dimensional crystals at the interface, the present invention makes it possible to align carbon nanotubes, carbon nanohorns with the use of the molecular arrangement ability of ferritin fused with nanographite structure recognition peptides.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: September 13, 2011
    Assignee: Japan Science and Technology Agency
    Inventors: Kiyotaka Shiba, Kenichi Sano, Kenji Iwahori
  • T CELL EPITOPES OF THE CYN D 1 ALLERGEN FROM BERMUDA GRASS POLLEN
    Publication number: 20110217325
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having Bermuda grass allergy and genetic sequences encoding same. These molecules are preferentially immunointeractive with T cells in subjects having a Bermuda grass pollen allergy. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Bermuda grass pollen or derivative or homologue thereof.
    Type: Application
    Filed: August 30, 2010
    Publication date: September 8, 2011
    Applicant: CIRCASSIA LIMITED
    Inventors: Robyn O'HEHIR, Jennifer ROLLAND
  • SYNTHETIC PEPTIDES CORRESPONDING TO OVERLAPPING NEUTRALIZING DETERMINANTS IN THE CBD1 EPITOPE INDUCE BROADLY NEUTRALIZING ANTIBODIES
    Publication number: 20110217307
    Abstract: The present invention relates to chimeric peptides having a caveolin-1 binding domain of an HIV-1 gp41 (CBD1) peptide or a variant of said CBD1, fused to a T helper epitope. In one aspect, the T epitope is from a peptide selected from the group consisting of a tetanus toxin, an HIV-1 Gag p24 and an HIV-1 Env-gp120. Compositions containing these chimeric peptides and pharmaceutical and immunogenic compositions as well as vaccines comprising these chimeric peptides also are part of the present invention. Methods to induce neutralizing antibodies against HIV-1 activity and uses of the chimeric peptides to treat or to prevent HIV-1 infection are also disclosed.
    Type: Application
    Filed: August 27, 2009
    Publication date: September 8, 2011
    Applicant: Centre National de la Recherche Scientifque (CNRS)
    Inventors: Ara Hovanessian, Bernard Krust
  • Use of stabilised synthetic compounds in immunoassay
    Patent number: 8013115
    Abstract: The invention concerns the use of at least a synthetic compound comprising: a carrier molecule having at least a hydrocarbon chain comprising at least 10, advantageously at least 12, preferably at least 14 and not more than 300, advantageously not more than 100, preferably not more than 50, selected'among C, N, O, S, P and Si, and comprising at least two reactive functions, or capable of reacting, for grafting lateral arms on said chain, and at least two different epitopes carried by said lateral arms grafted on said carrier molecule, as standard or control for immunoassay of said biological molecules, in particular of polypeptides or proteins.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: September 6, 2011
    Assignee: Bio-Rad Pasteur
    Inventors: Isabelle Nathalie Garric, Isabelle Karine Giuliani, Catherine Christiane Marie Larue, François Yves Rieunier, Sylvie Marie-France Trinquier
  • OBTAINING COCOA EXTRACTS RICH IN BIOACTIVE PEPTIDES WITH ACE AND PEP ENZYME INHIBITORY ACTIVITY
    Publication number: 20110213122
    Abstract: The present invention relates to obtaining bioactive peptides from plant raw materials, specifically cocoa extracts, by means of enzyme treatment. Said biopeptides have angiotensin converting enzyme (ACE) and prolyl endopeptidase enzyme (PEP) inhibitory activity in vitro and/or antioxidant activity in vivo, being able to be used in the food, dietetic and pharmaceutical industry.
    Type: Application
    Filed: August 1, 2008
    Publication date: September 1, 2011
    Applicants: NATRACEUTICAL, S.A., BIOPOLIS, S.L.
    Inventors: Begona Muguerza Marquinez, Honorato Monzo Oltra, Natalia Alepuz Rico, Esther Bataller Leiva, Salvador Genoves Martínez, Maria Enrique López, Patricia Martorell Guerola, Daniel Ramon Vidal
  • METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS
    Publication number: 20110213124
    Abstract: Methods and systems to generate 6-amino-6-deoxy-D-luciferin precursor, 2-cyano-6-aminobenzothiazole and related compounds and derivatives
    Type: Application
    Filed: February 28, 2011
    Publication date: September 1, 2011
    Inventors: Amy L. GRYSHUK, Julie Perkins
  • PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS
    Publication number: 20110212896
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Application
    Filed: September 16, 2010
    Publication date: September 1, 2011
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS
    Publication number: 20110212162
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Application
    Filed: February 10, 2011
    Publication date: September 1, 2011
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • BIOMARKERS FOR RHEUMATOID ARTHRITIS
    Publication number: 20110212470
    Abstract: The present invention relates to the diagnosis of autoimmune disorders, more specifically to the diagnosis of rheumatoid disorders, chronic autoimmune arthritis and even more specifically to the diagnosis of rheumatoid arthritis. A biomarker panel is provided which can be used to detect if a subject has rheumatoid arthritis. Also described are methods of identification of such biomarkers.
    Type: Application
    Filed: March 23, 2009
    Publication date: September 1, 2011
    Inventors: Veerle Somers, Klaartje Somers, Pieter Stinissen
  • VARIANTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR AND USE THEREOF
    Publication number: 20110212051
    Abstract: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.
    Type: Application
    Filed: February 28, 2011
    Publication date: September 1, 2011
    Inventors: Michal Ayalon-Soffer, Zurit Levine, Osnat Sella-Tavor, Alex Diber, Ronen Shemesh, Amir Toporik, Galit Rotman, Sergey Nemzer, Avi Rosenberg, Dvir Dahary, Assaf Wool, Gad S. Cojocaru, Pinchas Akiva, Sarah Pollock, Kinneret Savitsky, Jeanne Bernstein
  • LIGANDS TO RADIATION-INDUCED MOLECULES
    Publication number: 20110213293
    Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.
    Type: Application
    Filed: February 1, 2011
    Publication date: September 1, 2011
    Applicant: VANDERBILT UNIVERSITY
    Inventors: Dennis E. Hallahan, Shimian Qu, Zhaozhong Han
  • Yersinia SPP. Polypeptides and Methods of Use
    Publication number: 20110206674
    Abstract: The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 25, 2011
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Selectively Targeted Antimicrobial Peptides and the Use Thereof
    Publication number: 20110207657
    Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 25, 2011
    Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Fengxia Qi, Jian He, Ian H. McHardy, Maxwell H. Anderson
  • CD44 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, ANTIBODIES DIRECTED THEREAGAINST AND METHOD OF USING SAME FOR DIAGNOSING AND TREATING INFLAMMATORY DISEASES
    Publication number: 20110207678
    Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.
    Type: Application
    Filed: February 7, 2011
    Publication date: August 25, 2011
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: David Naor, Shlomo Nedvetzki, Itshak Golan, Irina Kessel, Lora Melnik
  • Sclerostin epitopes
    Patent number: 8003108
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: August 23, 2011
    Assignees: Amgen Inc., UCB SA
    Inventors: Hsieng Sen Lu, Christpher Paszty, Martyn Kim Robinson, Alistair James Henry, Kelly Sue Warmington, John Latham, Alastair Lawson, David Winkler, Aaron George Winters
  • COMBINATION THERAPY FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE, AND KIT THEREFOR
    Publication number: 20110201987
    Abstract: The invention relates to a method for preventing or treating Alzheimer's disease (AE). According to said method, a means for inducing a sequestration of amyloid ? (A?) into a plasma is administered to a person, and the person is treated by means of an apheresis device comprising a fixed carrier that can come into contact with the blood or plasma flow and comprises a receptor binding an amyloid-?-precurser-protein (APP), the APP being removed from the blood of the person by means of the apheresis device. The invention also relates to a set for carrying out said method.
    Type: Application
    Filed: March 11, 2011
    Publication date: August 18, 2011
    Applicant: AFFIRIS Forschungs-und Entwicklungs GmbH
    Inventors: Frank Mattner, Walter Schmidt
  • Peptide Ligand Directed Drug Delivery
    Publication number: 20110200527
    Abstract: Provided is a novel peptide ligand (Leu-Ala-Arg-Leu-Leu-Thr) for binding to an EGFR surface pocket based on its 3D crystal structure. When conjugated to the distal end of liposome surface PEG moieties, the peptide ligand directs liposome binding and uptake by EGFR high expressing cancer cells (H1299 and SPCA1) specifically and efficiently. The targeted delivery of liposomal anticancer drug doxorubicin results in better therapeutic efficacy towards cells in vitro. In vivo, the targeted liposomes are injected via tail vein and the time course of their distribution and accumulation in xenograft tumor tissues are studied using a live animal fluorescence imaging system. The LARLLT targeted liposomes were seen to gradually concentrate at the tumor site and be preferentially retained more than 80 hours after injection.
    Type: Application
    Filed: November 5, 2008
    Publication date: August 18, 2011
    Applicant: Shanghai Jiaotong University
    Inventors: Yuhong Xu, Shuxian Song, Dan Liu
  • Compositions and Methods for Inhibiting the Interaction between CFTR and CAL
    Publication number: 20110201544
    Abstract: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface.
    Type: Application
    Filed: October 20, 2009
    Publication date: August 18, 2011
    Inventors: Dean Madden, Patrick R. Cushing, Prisca Boisguerin, Rudolf Volkmer, Lars Vouilleme
  • METHOD AND KIT FOR DETECTING ANTIBODY TO AVIBACTERIUM PARAGALLINARUM
    Publication number: 20110201034
    Abstract: A method and a kit for detecting an antibody to Avibacterium paragallinarum are provided. A method for detecting an antibody to Avibacterium paragallinarum which comprises detecting an antibody induced by an outer-membrane protein of Avibacterium paragallinarum serotype A and/or serotype C by ELISA with a solid phase to which a peptide consisting of an amino acid sequence of non-homologous region of said outer-membrane protein or a portion thereof is immobilized, and a detection kit used for said method.
    Type: Application
    Filed: February 6, 2009
    Publication date: August 18, 2011
    Applicant: THE CHEMO-SERO-THERAPEUTIC RES INST
    Inventors: Toshihiro Ushijima, Takashi Imamura, Ryuichi Sakamoto, Masashi Sakaguchi
  • SYNTHETIC ANALOGS OF THE JUXTAMEMBRANE DOMAIN OF IGF1R AND USES THEREOF
    Publication number: 20110195911
    Abstract: A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits IFG-R1 activity, as well as a method of inhibiting a IGF1R in a cell, a method of treating or preventing IGF1R-mediated disease, and related compounds, compositions, and methods.
    Type: Application
    Filed: March 27, 2009
    Publication date: August 11, 2011
    Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Nadya I. Tarasova, Sergey G. Tarasov
  • STREPTOCOCCUS PYOGENES CLASSIFICATION
    Publication number: 20110195409
    Abstract: The difference Lancefield T-serotypes correlate with the sequence of the pilus backbone protein (Pbp) in Streptococcus pyogenes (GAS). We have sequenced Pbp for over 50 GAS strains, representing the major disease-associated serotypes, and have identified 15 Pbp variants. These 15 variants have been shown to determine the specificity of the T-serotyping, such that sequencing of the Pbp from a given GAS strain reliably predicts that strain's T-serotype. thus the invention permits the t-serotype of a GAS strain to be determined based on genotype.
    Type: Application
    Filed: November 6, 2008
    Publication date: August 11, 2011
    Applicant: Novartis Vaccines and Diagnostics SRL
    Inventors: Guido Grandi, Marirosa Mora, John L. Telford, Chiara Zingaretti, Fabiana Falugi
  • Dimeric Smac Mimetics
    Publication number: 20110195043
    Abstract: The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
    Type: Application
    Filed: October 28, 2010
    Publication date: August 11, 2011
    Inventors: Haizhou Sun, Xiaoming Xu, Ming Zhou, Susan Harran, Gunnar James Hanson, Lai Wang
  • csPCNA Isoform Modifications And Uses Thereof
    Publication number: 20110195510
    Abstract: Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed.
    Type: Application
    Filed: March 11, 2011
    Publication date: August 11, 2011
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Derek J. HOELZ, Robert J. HICKEY, Linda H. MALKAS
  • Artifical Pulmonary Surfactant Compositions
    Publication number: 20110195892
    Abstract: The peptides according to the present invention have a high surfactant activity, but no or little hemolytic activity and comprises D-amino acid and acids at a rate of approximately 5% to 40% of the structuring amino acids. The pulmonary surfactant composition of the present invention comprises a mixture of the peptide with a natural lecithin such as soy lecithin and so on Therefore, the pulmonary surfactant composition can be expected to be developed as a pulmonary surfactant without using any animal-derived substance, which has a high surfactant activity and can be produced at reasonable costs and on a large scale.
    Type: Application
    Filed: June 28, 2006
    Publication date: August 11, 2011
    Inventors: Sannamu Lee, Ko Yukitake, Yoshihiro Nakamura
  • Anti-Notch3 antibodies
    Patent number: 7994285
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: August 9, 2011
    Assignee: Genentech, Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
    Patent number: 7994278
    Abstract: The invention relates to therapeutic polypeptides isolated from beta-human chorionic gonadotropin (?-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: August 9, 2011
    Assignee: Nobel Biosciences LLC
    Inventors: Robert C. Gallo, Joseph Bryant, Yanto Lundardi-Iskandar
  • Applications For A New Class Of Enzymes: Sulfiredoxins
    Publication number: 20110189154
    Abstract: Applications of a new class of enzymes, sulfiredoxines (Srx), catalyzing the reduction of Cys-SO2#191H (sulfinic cystein acid) and the reduction of peroxyredoxine (Prx) in the Cys-SO2#191H form thereof into a thiol derivative.
    Type: Application
    Filed: July 2, 2004
    Publication date: August 4, 2011
    Inventors: Michel Toledano, Benoît Biteau
  • PEPTIDES THAT TARGET DORSAL ROOT GANGLION NEURONS
    Publication number: 20110189263
    Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.
    Type: Application
    Filed: January 30, 2009
    Publication date: August 4, 2011
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
  • NOVEL ANTIVIRAL COMPOUNDS FROM MARINE EXTRACTS
    Publication number: 20110189221
    Abstract: The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza.
    Type: Application
    Filed: January 14, 2011
    Publication date: August 4, 2011
    Inventors: Alberto van Olphen, Bill J. Baker, Dennis E. Kyle, Cynthia Bucher, Alan Maschek, James B. McClintock, JR., Charles D. Amsler
  • Antibody Targeting Through a Modular Recognition Domain
    Publication number: 20110189206
    Abstract: Antibodies containing one or more modular recognition domains (MRDs) used to target the antibodies to specific sites are described. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.
    Type: Application
    Filed: December 24, 2008
    Publication date: August 4, 2011
    Inventor: Carlos F. Barbas, III
  • Multiblock copolymers having improved mechanical properties
    Patent number: 7989586
    Abstract: Replacement of the amorphous peptide domain of a structural biopolymer, such as silk from silkworms or spiders, with a nonpeptide segment while maintaining the ?-sheet forming crystalline segments provides synthetic multiblock copolymers having solid-state structures and mechanical properties similar to the naturally occurring structural biopolymer is described herein. Such synthetic multiblock copolymers may be produced as films or fibers.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: August 2, 2011
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Osman Rathore, Dotsevi Y. Sogah
  • MELANOCORTIN RECEPTOR LIGANDS
    Publication number: 20110183886
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: March 29, 2011
    Publication date: July 28, 2011
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS
    Publication number: 20110183919
    Abstract: The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme.
    Type: Application
    Filed: September 11, 2009
    Publication date: July 28, 2011
    Applicant: CADILA PHARMACEUTICALS LTD.
    Inventors: Bakulesh Mafatlal Khamar, Singh Chandan, Rajiv Indravadan Modi
  • SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS
    Publication number: 20110183889
    Abstract: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.
    Type: Application
    Filed: August 28, 2008
    Publication date: July 28, 2011
    Applicant: The Regents of the University of California
    Inventors: Alan M. Fogelman, Mohamad Navab
  • Methods and systems for annotating biomolecular sequences
    Publication number: 20110183924
    Abstract: A method of annotating biomolecular sequences. The method comprises (a) computationally clustering the biomolecular sequences according to a progressive homology range, to thereby generate a plurality of clusters each being of a predetermined homology of the homology range; and (b) assigning at least one ontology to each cluster of the plurality of clusters, the at least one ontology being: (i) derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or (ii) generated from analysis of the at least one biomolecular sequence of each cluster thereby annotating biomolecular sequences.
    Type: Application
    Filed: April 23, 2010
    Publication date: July 28, 2011
    Applicant: Compugen Ltd.
    Inventors: Liat Mintz, Hanqing Xie, Dvir Dahary, Erez Levanon, Shiri Freilich, Nili Beck, Wei-Yong Zhu, Alon Wasserman, Jeanne Bernstein
  • Use of Agonists of Integrin Alpha 5 for Inducing the Osteogenic Differentiation of Mesenchymal Stem Cells
    Publication number: 20110182916
    Abstract: The invention relates to the use of agonists of integrin alpha for promoting osteoblast differentiation of mesenchymal stem cells. These agonists are useful in particular for enhancing osteogenesis in the treatments of diseases associated with bone loss or insufficient bone formation.
    Type: Application
    Filed: August 5, 2009
    Publication date: July 28, 2011
    Inventors: Pierre Marie, Fromigue Olivia, Hamidouche Zahira
  • PLECTIN-1 TARGETED AGENTS FOR DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA
    Publication number: 20110182814
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Application
    Filed: April 14, 2009
    Publication date: July 28, 2011
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Peptide-Polymer Cell Culture Articles and Methods of Making
    Publication number: 20110183418
    Abstract: Functionalized peptide monomers, peptides that have been functionalized to contain a polymerization moiety, are disclosed. The use of these functionalized peptide monomers to form peptide polymers which are useful as synthetic surfaces capable of supporting culture of cells in culture, particularly cells that will be used therapeutically, is also disclosed. Methods of making the surfaces and methods of using the surfaces are also disclosed.
    Type: Application
    Filed: July 28, 2010
    Publication date: July 28, 2011
    Inventors: Arthur Winston Martin, Jodelle Karen Nelson, Christopher Bankole Shogbon, David Michael Weber, Yue Zhou
  • Peptides for preventing or treating liver damage
    Patent number: 7985734
    Abstract: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: July 26, 2011
    Inventors: Yun Cheng, Ruihe Yu, Wan Zhou Zhao, Jun Zhao, Jing Li
  • ANTIGENIC TAU PEPTIDES AND USES THEREOF
    Publication number: 20110177109
    Abstract: The present disclosure relates to novel immunogens and compositions comprising an antigenic tau peptide, preferably linked to an immunogenic carrier for use in the treatment of tau-related neurological disorders. The disclosure further relates to methods for production of these immunogens and compositions and their use in medicine.
    Type: Application
    Filed: July 29, 2010
    Publication date: July 21, 2011
    Applicant: PFIZER VACCINES LLC
    Inventors: George Joseph Smith, III, Kenneth Nelson Wills, Jeff Xianchao Zhu
  • USE OF PEPTIDES FOR PROMOTING WOUND HEALING
    Publication number: 20110178010
    Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.
    Type: Application
    Filed: January 7, 2009
    Publication date: July 21, 2011
    Inventors: Johannes Gerhardus Maria Bolscher, Arie Van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem Van't Hof, Kamran Nazmi, Petronella Adriana Maria Van Den Keijbus
  • NOVEL P2X7 EPITOPES
    Publication number: 20110177080
    Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.
    Type: Application
    Filed: September 12, 2008
    Publication date: July 21, 2011
    Applicant: Biosceptre International Limited
    Inventors: Julian Alexander Barden, Angus Gidley-Baird